György
Gyorgy Andor, Budapest HU
Patent application number | Description | Published |
---|---|---|
20100197666 | (THIO) -CARBAMOYL-CYCLOHEXANE DERIVATIVES AND METHOD FOR TREATING SCHIZOPHRENIA - The present invention relates to use of (thio)-carbamoyl-cyclohexane derivatives, particularly trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of schizophrenia. Furthermore, the present invention relates to the treatment of schizophrenia through the administration of (thio)-carbamoyl cyclohexane derivatives, particularly trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and pharmaceutically acceptable salts thereof. | 08-05-2010 |
20100197704 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING ACUTE MANIA - The present invention relates to use of (thio)-carbamoyl-cyclohexane derivatives, particularly trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of acute mania. Furthermore, the present invention relates to the treatment of acute mania through the administration of (thio)-carbamoyl cyclohexane derivatives, particularly trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and pharmaceutically acceptable salts thereof. | 08-05-2010 |
Gyorgy Bekes, Szeged HU
Patent application number | Description | Published |
---|---|---|
20090097726 | SYSTEMS, METHODS AND APPARATUS AUTOMATIC SEGMENTATION OF LIVER IN MULTIPHASE CONTRAST-ENHANCED MEDICAL IMAGES - Systems, method and apparatus in which some embodiments of automatic segmentation of a liver parenchyma from multiphase contrast-enhanced computed-tomography images includes analyzing an intensity change in the images belonging to the different phases in order to determine the region-of-interest of the liver, thereafter segmenting starting from the region-of-interest and incorporating anatomical information to prevent oversegmentation, and thereafter combining the information of all available images. | 04-16-2009 |
Gyorgy Bolgar, Budapest HU
Patent application number | Description | Published |
---|---|---|
20090255599 | Insertion piece to a single-grip mixing faucet - The invention relates to an insertion piece to a single-grip mixing faucet developed as a control unit with a ceramic insertion, and on its one side it is connected to a footing, on its other side to a driving arm, the control unit itself, the cartridge, comprises a fixed stationary inlet disc and a moving control disc arranged one above the other to form together a plane sealing. The other side of the inlet disc is coupled to a footing, whereas the control disc on its side opposite to the inlet disc is in a forced connection with a ceramic moving element, which, in turn, is in connection with the driving arm. On the footing, a warm water inlet, a cold water inlet and an outlet are situated. | 10-15-2009 |
20100006169 | Insertion to a single-grip, rotation-operated mixing faucet - The invention relates to a single-grip, rotational mixing faucet insertion piece developed as a control unit with ceramic insertion, which is connected in its one face to a base, on its other face to an operation arm. The control unit, the so-called cartridge comprises a fixed stationary inlet disc and an adjustable control disc placed one above the other forming thereby a plane seal. The other face of the inlet disc is connected to the base, whereas the side of the control disc opposite to the inlet disc is connected to the operating arm. The base contains an inlet for the hot water, and an inlet for the cold water and an outlet. | 01-14-2010 |
20110146821 | INSERTION FOR SINGLE-GRIP MIXING FAUCET WITH INCREASED COMFORT ANGLE - The invention relates to single-grip mixing faucet comprising a control unit with ceramic insertion piece, so-called cartridge, one side of the cartridge is connected to a footing, the other side to an operating arm, the cartridge comprising a fixed, stationary inlet disc one side of which is connected to one side of a movable control disc and the two discs forming together a plane sealing, and forming a mixing space at the same time the opposite side of the inlet disc is in connection with the footing, whereas at the opposite side of the control disc is in driving connection with a ceramic disc mover, which, in turn, is connected to the operating arm, further on the footing cold water inlet and hot water inlet and an outlet for water flowing out are arranged. | 06-23-2011 |
Gyorgy Bozoki, Plano, TN US
Patent application number | Description | Published |
---|---|---|
20120124462 | Web Application Optimization - A method of optimizing a web page includes selecting an original web application code. A server-side executable associated with the original web application code is identified, and an object used in the server-side executable is identified. An evaluation is made of how the server-side executable uses the object. Then a determination is made as to whether substitute instructions, which provide functionality similar to that of the object, provides all of the functionality of the object that is used by the server-side executable. If so, then the original web application code is modified to use the substitute instructions. | 05-17-2012 |
20120124488 | Network Client Optimization - A method of rendering an optimized web page or other resource includes requesting a resource and receiving a response including a user interface control declaration and a data array containing properties for the user interface control. The data array is parsed to produce a first property value, and a property of the user interface control is modified to correspond to the first property value. Alternatively, the response may not include a user interface control declaration, but a user interface control may be instantiated having a property that corresponds to the first property value. The property value may have been determined dynamically based at least in part on information provided with the request. | 05-17-2012 |
20120124555 | Optimization of Compiled Control Objects - A method of optimizing a compiled control, for example a user interface control, includes generating a source code document including a test instruction statement that accesses an element of the control. The source code is then compiled, and one or more matched instructions in the compiled document are identified that correspond to the test instruction statement. A pattern is then formed using the one or more matched instructions. | 05-17-2012 |
Gyorgy Csako, Rockville, MD US
Patent application number | Description | Published |
---|---|---|
20090011974 | Scavenger Receptor B1 (Cla-1) Targeting for the Treatment of Infection, Sepsis and Inflammation - This invention relates to methods and compositions for the treatment of sepsis, inflammation or infection. In particular, the invention concerns the use of molecule(s) that target SR-BI, which is also referred to as CLA-1 (SR-BI/CLA-1), to treat sepsis, bacterial and viral infections, and inflammatory diseases. SRB I/CLA- | 01-08-2009 |
Gyorgy Csapo, Boszormenyi HU
Patent application number | Description | Published |
---|---|---|
20090057217 | Apparatus for contaminant recovery - A contaminant recovery apparatus may have a sprayer attached to a front portion of the apparatus and operative to delivery droplets of molten wax to oil spilled in water or on ground. The apparatus may further comprise a take up system which picks up wax after it has solidified and absorbed the oil. The take up system may be attached to the rearward portion of the apparatus. The apparatus may also have a separation system which separates the wax and the oil. The reclaimed wax can be reused to pick up more spilled oil. The reclaimed oil may be refined for fuel. | 03-05-2009 |
Gyorgy Csatadi, Nagykovacs HU
Patent application number | Description | Published |
---|---|---|
20090164881 | Scan-to-Redact Searchable Documents - An automatic scan-to-redacted electronic document is described. A user input is received which identifies a scanned document. Then the scanned document is automatically processed to produce a corresponding redacted document which having searchable document text and a document image. The searchable document text includes coded redaction text satisfying defined redaction parameters. The document image includes redacted image areas corresponding to redacted elements. | 06-25-2009 |
Gyorgy Csefan, Gyula HU
Patent application number | Description | Published |
---|---|---|
20120129505 | GENERATING RELATIONAL INDICATORS BASED ON ANALYSIS OF TELECOMMUNICATIONS EVENTS - A system for generating a relational indicator based on analysis of at least one telecommunications event between a first party and a second party, comprises: a relation management engine which is configured to process first content characteristics extracted from a plurality of telecommunications events to produce a first relation parameter and to process second content characteristics extracted from the plurality of telecommunications events to produce a second relation parameter; a terminal device configured to use the first and second relation parameters to generate the relational indicator. | 05-24-2012 |
Gyorgy Ferenczy, Budapest HU
Patent application number | Description | Published |
---|---|---|
20080287434 | New amino-alkyl-amide derivatives as CCR3 receptor ligands - The invention relates to a compound of the general formula (I), | 11-20-2008 |
20080293745 | New amino-alkyl-amide derivatives as CCR3 receptor ligands - The invention relates to a compound of the general formula (I), | 11-27-2008 |
20140288106 | CYCLOALKANE CARBOXYLIC ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS - The present invention relates to compounds of formula 1 | 09-25-2014 |
20150073004 | SUBSTITUTED B-AMINO ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS - The present invention relates to compounds of formula 1 | 03-12-2015 |
Gyorgy Gajari, Pilisvorosvar HU
Patent application number | Description | Published |
---|---|---|
20110011165 | METHOD FOR PLANNING ROAD ASPHALTS - The subject of the present invention is a new method for designing road asphalts, comprising:—the determination of the optimal bitumen content with compacting experiments using samples made of asphalt mixtures; the optimal bitumen content being the one at which the receptive void volume has a minimum value, depending on the bitumen content; that is, where the compactness of the sample is the highest, and by changing the mass rates in the asphalt mixture, the bitumen content is set to the optimal bitumen content at most. The optimal bitumen content provides the possibility to aim for reaching the highest compactness, i.e. the smallest possible void volume which provides the most favorable fatigue and solidity characteristics. | 01-20-2011 |
Gyorgy Galik, Albertirsa HU
Patent application number | Description | Published |
---|---|---|
20080200668 | Industrial Process for the Preparation of 17-Hydroxy-6Beta, 7Beta; 15Beta, 16Beta-Bismethylene-3-Oxo-17Alpha-Pregn-4-Ene-21-Carboxylic Acid Y-Lactone and Key Intermediates for this Process - The invention relates to an industrial process for the preparation of 17-hydroxy-6β,7β;15β,16β-bismethylene-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone of formula (I), and to the key-intermediates for this process. | 08-21-2008 |
Gyorgy Hasko, Scotch Plains, NJ US
Patent application number | Description | Published |
---|---|---|
20090041751 | Sepsis Prevention Through Adenosine Receptor Modulation - Methods for treating sepsis or septic shock in a patient comprising administering to said patient a therapeutically effective amount of a composition containing an adenosine A | 02-12-2009 |
Gyorgy Hasko, Gillette, NJ US
Patent application number | Description | Published |
---|---|---|
20150209413 | ATTENUATING OR TREATING SEPSIS OR SEPTIC SHOCK - Methods for attenuating or treating, or reducing the mortality of sepsis or septic shock using an ectonucleotidase such as CD39 or CD73 are provided. | 07-30-2015 |
Gyorgy Karlovits, Papuszy PL
Patent application number | Description | Published |
---|---|---|
20150208686 | NEW FAT BLEND COMPOSITION - Fat blend composition having 20% or less saturated fatty acids among which: 38% or less are palmitic acid; and 20% or more stearic acid; the fat blend being made at 5% to 100% hardstock containing 5% to 100% one or further hard fat and at least 5% stearic acid. Hardstock composition free of palm oil and its fractions having: 20% to 100% one or further hard fat being a fully hydrogenated oil, fractionated oil or fat, and/or interesterified oil or fat containing more than 15% stearic acid; and 0% to 80% of one or further natural or fractionated oil or fat chosen among canola, sunflower, low erucic acid rapeseed, high oleic sunflower, soybean, corn, peanut, olive, high oleic canola, low linolenic soybean, and high stearic sunflower oils, shea butter, cocoa butter and coconut fat, the natural or fractionated oil or fat being mixed and/or interesterified with the hard fat. | 07-30-2015 |
Gyorgy Krasznay, Budapest HU
Patent application number | Description | Published |
---|---|---|
20090137563 | PROCESS FOR THE PREPARTION OF OLANZAPINE - The invention relates to a process for the preparation of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno-[2,3-b][1,5]benzodiazepine (olanzapine) of the formula (I) by reacting 4-amino-2-methyl-10H-thieno [2,3-b][1/5]benzodiazepine hydrochloride of the formula (II) with N-methylpiperazine in an organic solvent, which comprises carrying out the reaction in the mixture of toluene and 1,3-dimethyl-2-imidazolidinone. The invention also encompasses new 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno [2,3-b][1,5]benzodiazepine dihydrochloride trihydrate of the formula (IB), the preparation thereof and pharmaceutical compositions comprising said new compound. | 05-28-2009 |
Gyorgy Lipovszki, Budapest HU
Patent application number | Description | Published |
---|---|---|
20100116734 | BIOLOGICAL WASTEWATER TREATMENT APPARATUS AND METHODS USING MOVING BELT CONTRACTOR - A compact biological treatment assembly, apparatus and methods are disclosed, the apparatus including a movable belt biological contactor having selected microbial cultures established thereon. The apparatus further includes a tank having a volume for receipt of wastewater to be treated, first and second drums positioned at the tank each connected to an end of the belt contactor, and a motor or motors together with a controller for rotating the drums cooperatively to move the belt contactor between the drums thereby coiling and uncoiling the belt contactor on the drums. | 05-13-2010 |
20110257788 | Mobile station and methods for diagnosing and modeling site specific full-scale effluent treatment facility requirements - A mobile station and methods are disclosed for diagnosing and modeling site specific effluent treatment facility requirements to arrive at a treatment regimen and/or proposed commercial plant model idealized for the particular water/site requirements. The station includes a mobile platform having power intake, effluent intake and fluid outflow facilities and first and second suites of selectably actuatable effluent pre-treatment apparatus. An effluent polishing treatment array is housed at the station and includes at least one of nanofiltration, reverse osmosis and ion-exchange stages. A suite of selectively actuatable post-treatment apparatus is housed at the station. Controls are connected at the station for process control, monitoring and data accumulation. A plurality of improved water treatment technologies is also disclosed. The modeling methods include steps for analyzing raw effluent to be treated, providing a field of raw effluent condition entry values and a field of treated effluent condition goals entry values, and utilizing said fields to determine an initial treatment model including a selection of, and use parameters for, treatment technologies from the plurality of down-scaled treatment technologies at the facility, the model dynamically and continuously modifiable during treatment modeling. | 10-20-2011 |
20140332450 | Mobile station for diagnosing and modeling site specific effluent treatment facility requirements - A mobile station and methods are disclosed for diagnosing and modeling site specific effluent treatment facility requirements to arrive at a treatment regimen and/or proposed commercial plant model idealized for the particular water/site requirements. The station includes a mobile platform having power intake, effluent intake and fluid outflow facilities and first and second suites of selectably actuatable effluent pre-treatment apparatus. An effluent polishing treatment array is housed at the station and includes at least one of nanofiltration, reverse osmosis and ion-exchange stages. A suite of selectively actuatable post-treatment apparatus is housed at the station. Controls are connected at the station for process control, monitoring and data accumulation. A plurality of improved water treatment technologies is also disclosed. The modeling methods include steps for analyzing raw effluent to be treated, providing a field of raw effluent condition entry values and a field of treated effluent condition goals entry values, and utilizing said fields to determine an initial treatment model including a selection of, and use parameters for, treatment technologies from the plurality of down-scaled treatment technologies at the facility, the model dynamically and continuously modifiable during treatment modeling. | 11-13-2014 |
Gyorgy Lipovszki, Verbena HU
Patent application number | Description | Published |
---|---|---|
20090032446 | Mobile station and methods for diagnosing and modeling site specific effluent treatment facility requirements - A mobile station and methods are disclosed for diagnosing and modeling site specific effluent treatment facility requirements to arrive at a treatment regimen and/or proposed commercial plant model idealized for the particular water/site requirements. The station includes a mobile platform having power intake, effluent intake and fluid outflow facilities and first and second suites of selectably actuatable effluent pre-treatment apparatus. An effluent polishing treatment array is housed at the station and includes at least one of nanofiltration, reverse osmosis and ion-exchange stages. A suite of selectively actuatable post-treatment apparatus are housed at the station. Controls are connected at the station for process control, monitoring and data accumulation. A plurality of improved water treatment technologies are also disclosed. | 02-05-2009 |
Gyorgy Lipusz, Bekes HU
Patent application number | Description | Published |
---|---|---|
20100083627 | HARVESTER ADAPTER WITH STALK SHREDDER FOR HARVESTING GRAIN CROPS, PARTICULARLY SUNFLOWER - The invention relates to a harvester adapter with stalk shredder for harvesting grain crops, particularly sunflower, comprising a frame structure attached to a combine harvester, and at least two crop gathering units having a snout, where the crop gathering units are secured to the frame structure. Neighbouring crop gathering units are arranged such that a channel with an open leading end is formed between them, with a stalk gathering unit being disposed in driving connection with a harvesting mechanism on at least one side of the channels. The adapter has a collecting auger disposed rearward from the harvesting mechanism and at least one stalk shredder unit attached to the frame structure. The speed of the stalk gathering unit ( | 04-08-2010 |
Gyorgy Lustyik, Pecs HU
Patent application number | Description | Published |
---|---|---|
20080293585 | 5'/3' Ratioing Procedure for Detection of Gene Rearrangements - The present invention relates to methods and kits useful for the detection of gene rearrangements and the diagnosis of a propensity to develop a disease condition caused by the gene rearrangements, wherein two PCR products are prepared from the 5′ side and from the 3′ side of a putative breakpoint of the gene of interest, and the ratio of the two products are measured. | 11-27-2008 |
Gyorgy Marko-Varga, Lund SE
Patent application number | Description | Published |
---|---|---|
20080227117 | Peptides as Biomarkers of Copd - The present invention relates to the identification of biomarkers for the disease condition COPD. The uses of such biomarkers in diagnosis and therapy and a novel method for their identification is are also described. | 09-18-2008 |
20100203565 | Peptide Fingerprint from the Degradation of Elastin by HNE - Methods for producing and using protein/peptide fingerprints, derived from elastin degraded by the enzyme human Neutrophil Elastase (HNE), allowing identification and investigation of disease-associated proteins/peptides that can be linked to specific drug targets, or to specific drug target combinations. The methods are particularly useful for studies relating to Chronic Obstructive Pulmonary Disease (COPD). | 08-12-2010 |
Gyorgy Medgyesi, Budapest HU
Patent application number | Description | Published |
---|---|---|
20080247516 | Cable Guiding for a Ceiling Support of an X-Ray Device - The invention relates to a ceiling support system for a movable component ( | 10-09-2008 |
20090154653 | DRIVE UNIT FOR X-RAY SYSTEM - The invention relates to a drive unit ( | 06-18-2009 |
Gyorgy Morovjan, Budapest HU
Patent application number | Description | Published |
---|---|---|
20090111829 | Aripiprazole Salts - The present invention provides for new salts of aripiprazole of the general formula (II) formed with dibasic organic acids, camphorsulfonic acid, phosphoric acid, and processes for their preparation. Further objects of the present invention are pharmaceutical compositions containing said new aripiprazole salts. Aripiprazole salts according to present invention can be prepared by the reaction of aripiprazole base and suitable acid compounds in a molar ratio 0.5-3 based on the molar amount of aripiprazole in a suitable organic solvent. | 04-30-2009 |
20130338360 | METHOD FOR THE PREPARATION OF HIGH-PURITY PHARMACEUTICAL INTERMEDIATES - The present invention is related to intermediates useful in the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid and polymorphs of said intermediates, methods for preparation thereof and use thereof. | 12-19-2013 |
20150094345 | PHARMACEUTICAL FORMULATION HAVING IMPROVED STABILITY - The present invention is related to a pharmaceutical formulation containing ramipril with improved stability, which comprises ramipril and a desintegrant directly granulated with a binder. | 04-02-2015 |
Gyorgy Ordody, San Francisco, CA US
Patent application number | Description | Published |
---|---|---|
20100031196 | METHOD AND APPARATUS FOR SELECTING AND HIGHLIGHTING OBJECTS IN A CLIENT BROWSER - A computer implemented method, apparatus, article of manufacture and storage medium, provide the ability to select and highlight objects. A rendered image (containing one or more rendered objects) is displayed in a client browser on a client computer. A run length encoded (RLE) selection buffer is received, from a server across a network, into the client browser. The selection buffer provides a mapping of each pixel from the rendered image to rendered objects. User input is accepted that identifies a location of a cursor with respect to the rendered image. A determination is made, on the client computer, regarding which of the rendered objects has been selected based on the user input and the RLE selection buffer. The selected rendered object is then displayed in a visually distinguishable manner. | 02-04-2010 |
Gyorgy Petrovics, Bethesda, MD US
Patent application number | Description | Published |
---|---|---|
20080269157 | Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations - Alterations in ERG gene expression can be observed in patients with prostate cancer. Specific ERG isoforms are associated with, or involved in, prostate cancer. Compositions comprising these isoforms provide therapeutic benefit and can be used in methods of detecting, diagnosing, prognosing, and treating prostate cancer. These compositions provide biomarkers for detecting the expression of combinations of the PSA/KLK3, PMEPA1, NKX3.1, ODC1, AMD1, and ERG genes. | 10-30-2008 |
20090170075 | Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer - The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene. | 07-02-2009 |
20100144832 | Prostate Cancer-Specific Alternations in ERG Gene Expression and Detection and Treatment Methods Based on Those Alterations - The disclosure describes alterations in ERG gene expression. ERG isoforms and promoter sequence of the ERG gene that are involved in, or associated with, prostate cancer are provided. The disclosure further provides therapeutic compositions and methods of detecting, diagnosing, prognosing, and treating prostate cancer, including biomarkers for detecting the expression of two or more of the following genes: PSA/KLK3, PMEPA1, NKX3.1, ODC1, AMD1, and ERG. | 06-10-2010 |
20120295282 | METHODS OF DIAGNOSING OR TREATING PROSTATE CANCER USING THE ERG GENE, ALONE OR IN COMBINATION WITH OTHER OVER OR UNDER EXPRESSED GENES IN PROSTATE CANCER - The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene. | 11-22-2012 |
20130029860 | Methods Of Diagnosing Or Treating Prostate Cancer Using The ERG Gene, Alone Or In Combination With Other Over Or Under Expressed Genes In Prostate Cancer - The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene. | 01-31-2013 |
20130281674 | Methods of Diagnosing or Treating Prostate Cancer Using The ERG Gene, Alone or in Combination with Other Over or Under Expressed Genes in Prostate Cancer - The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene. | 10-24-2013 |
20150044670 | PROSTATE CANCER-SPECIFIC ALTERATIONS IN ERG GENE EXPRESSION AND DETECTION AND TREATMENT METHODS BASED ON THOSE ALTERATIONS - The disclosure describes alterations in ERG gene expression. ERG isoforms and promoter sequence of the ERG gene that are involved in, or associated with, prostate cancer are provided. The disclosure further provides therapeutic compositions and methods of detecting, diagnosing, prognosing, and treating prostate cancer, including biomarkers for detecting the expression of two or more of the following genes: PSA/KLK3, PMEPA1, NKX3.1, ODC1, AMD1, and ERG. | 02-12-2015 |
20150045240 | Methods of Diagnosing or Treating Prostate Cancer Using the ERG Gene, Alone or in Combination with Other over or Under Expressed Genes in Prostate Cancer - The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene. | 02-12-2015 |
20150176078 | PROSTATE CANCER GENE EXPRESSION PROFILES - The present disclosure provides gene expression profiles that are associated with prostate cancer. The gene expression profiles can be used to detect prostate cancer cells in a sample and to distinguish between well differentiated (WD) prostate cancer and poorly differentiated (PD) prostate cancer. Also provided is an array comprising oligonucleotide probes for detecting the unique gene signature associated with WD and/or PD prostate cancer. | 06-25-2015 |
Gyorgy Posfai, Szeged HU
Patent application number | Description | Published |
---|---|---|
20090075333 | Reduced Genome E. Coli - Reduced genome strains of | 03-19-2009 |
20120219994 | PROPHAGE ELEMENT-FREE BACTERIA - The present invention provides a bacterium having a genome that is genetically engineered to be smaller than the genome of its native parent strain. A bacterium with a smaller genome can produce a commercial product more efficiently. The present invention also provides methods for deleting genes and other DNA sequences from a bacterial genome. The methods provide precise deletions and seldom introduces mutations to the genomic DNA sequences around the deletion sites. Thus, the methods can be used to generate a series of deletions in a bacterium without increasing the possibility of undesired homologous recombination within the genome. In addition, some of the methods provided by the present invention can also be used for replacing a region of a bacterial genome with a desired DNA sequence. | 08-30-2012 |
20130011874 | REDUCED GENOME E. COLI - Reduced genome strains of | 01-10-2013 |
20140302555 | Reduced Genome Bacteria With Improved Genetic Stability - Reduced genome bacteria with improved genetic stability are provided. Also provided are methods of producing polypeptides using the reduced genome bacteria with improved genetic stability. | 10-09-2014 |
20150344838 | REDUCED GENOME E. COLI - Reduced genome strains of | 12-03-2015 |
Gyorgy Ruzsics, Budapest HU
Patent application number | Description | Published |
---|---|---|
20120330018 | PROCESS FOR PREPARING PHARMACEUTICAL COMPOUNDS AND INTERMEDIATE COMPOUNDS - The object of the present invention is a process for preparing the 2-acetoxy-5-(2-fluor-α-cyclopropyl-carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-tieno[3,2-c]pyridine (prasugrel) of the formula (I). The process starts form crystalline 5-trityl-4,5,6,7-tetrahydro-tieno[3,2-c]pyridine of the formula (VI). Further objects of the present invention are two novel crystalline forms of 5-trityl-4,5,6,7-tetrahydro-tieno[3,2-c]pyridine of the formula (VI) and the use thereof for preparing the compound of the formula (V) and process preparing thereof. | 12-27-2012 |
20130030183 | PROCESS FOR PREPARING A PHARMACEUTICAL COMPOUND - The object of the present invention is a one-pot process for preparing the 2-acetoxy-5-(2-fluoro-α-cyclopropyl-carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-tieno[3,2-c]-pyridine (prasugrel) of the formula (I) by reacting the 5,6,7,7a-tetrahydro-4H-tieno[3,2-c]-pyridine-2-on of the formula (II) with 2-bromo-1-cyclopropyl-2-(2-fluorophenyl)-etanone of the formula (III) or with 2-chloro-1-cyclopropyl-2-(2-fluorphenyl)-etanone of the formula (IIIa) and acetylating of the formed compound of the formula (IV), wherein the reaction is carried out in the presence of an organic base with an acetylation agent without isolating the compound of the formula (IV). The coupling and acetylation are carried out in the presence of the same organic base such as triethylamine, N,N-diisopropyl-ethylamine or pyridine. At the end of the process the prasugrel of the formula (I) is purified by recrystallization from an organic solvent or a mixture of solvents. | 01-31-2013 |
20130281694 | METHOD FOR PREPARING ROSUVASTATIN SALTS - The present invention is related to methods for the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S,6E)-dihydroxy-hept-6-enoic acid, intermediates thereof and methods for producing said intermediates. | 10-24-2013 |
20130338360 | METHOD FOR THE PREPARATION OF HIGH-PURITY PHARMACEUTICAL INTERMEDIATES - The present invention is related to intermediates useful in the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid and polymorphs of said intermediates, methods for preparation thereof and use thereof. | 12-19-2013 |
20140142303 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS - The invention relates to a process for the preparation of 5-chloro-N-({(5-S)-2-oxo3-[4-(3-oxo-morj)holine-4-yl)-phenyl]-1,3-oxazolidine-5-yl}-methyl) thiophen-2-carboxamide having the INN rivaroxaban. The process is characterized by the reactions according to claim | 05-22-2014 |
20140155614 | PHARMACEUTICAL INTERMEDIATES AND PROCESS FOR THE PREPARATION THEREOF - The present invention relates to a process for the preparation of dabigatran etexilate of the formula | 06-05-2014 |
Gyorgy Ruzsics, Hogyesz HU
Patent application number | Description | Published |
---|---|---|
20090215855 | New Crystalline Atorvastatin Hemicalcium Salt Polymorph Form - The present invention relates to a new crystalline polymorph B-52 form of atorvastatin hemicalcium salt [A[(3R,5R)-7-[3-phenyl-4-[(phenyl carbamoyl]-2-(4-fluorophenyl)-5-(1-methylethyl)-1H-pyrrole-1-yl]-3,5-dihydroxy-heptanoic acid calcium salt (2:1)], medicinal preparations containing the new polymorph form, process for the preparation thereof and the use of the new polymorph form for the preparation of medicinal products. | 08-27-2009 |
Gyorgy Stampf, Budapest HU
Patent application number | Description | Published |
---|---|---|
20090253712 | AQUEOUS SOLVENT SYSTEM FOR SOLUBILIZATION OF AZOLE COMPOUNDS - A pharmaceutical composition includes: | 10-08-2009 |
Gyorgy Strausz, Budaors HU
Patent application number | Description | Published |
---|---|---|
20150122178 | REACTION CHAMBER FOR DEPOSITION OF A SEMICONDUTOR LAYER ON THE PLURALITY SUBSTRATES IN BATCHES - A reaction chamber for deposition of a semiconductor layer or layer structure on the plurality of substrate surfaces in substrate batches wherein the chamber comprises a body with an inner volume and a closing bottom lid, in the inner volume rectangular substrates are aranged spaced apart from each other and electrodes suitable for providing high-frequency electromagnetic field are disposed between the substrates; and the space presenting between the surfaces to be deposited provide flow channels making available the laminar flow of reaction gases between two opposite sides of the chamber, and the chamber is characterized in that the closing bottom lid can be opened in the vertical up-and-down direction, and the lid comprises supporting frames for holding the substrates from the bottom and along the side edges, and the supporting frames are provided with adequate recesses to enable them to perform this supporting function. | 05-07-2015 |
Gyorgy Vamosi, Debrecen HU
Patent application number | Description | Published |
---|---|---|
20090180966 | Cancer cell diagnosis by targeting delivery of nanodevices - Macromolecular contrast agents for magnetic resonance imaging are described. Biomolecules and their modified derivatives form stable complexes with paramagnetic ions thus increasing the molecular relaxivity of carriers. The synthesis of biomolecular based nanodevices for targeted delivery of MRI contrast agents are described. Nanoparticles (NP) have been constructed by self-assembling of chitosan (CHIT) as polycation and poly-gamma glutamic acids (PGA) as polyanion. NP's are capable of Gd-ion uptake forming a particle with suitable molecular relaxivity. Folic acid (FA) is linked to the NP's to produce NP-FA bioconjugates that can be used for targeted in vitro delivery to a human cancer cell line. | 07-16-2009 |
Gyorgy Vikor, Oroshaza HU
Patent application number | Description | Published |
---|---|---|
20150345206 | IG WINDOW UNIT FOR PREVENTING BIRD COLLISIONS - This invention relates to a window designed to prevent or reduce bird collisions therewith. In certain example embodiments, the window may include an insulating glass (IG) window unit having first and second substrates spaced apart from one another, wherein at least one of the substrates supports an ultraviolet (UV) reflecting coating for reflecting UV radiation so that birds are capable of more easily seeing the window. By making the window more visible to birds, bird collisions and thus bird deaths can be reduced. | 12-03-2015 |
Gyorgy Vukics, Urhajos HU
Patent application number | Description | Published |
---|---|---|
20090153016 | COLORED FLUORESCENT LAMP - A colored fluorescent lamp is provided. The lamp comprises an envelope having an inner surface, means for providing discharge within the envelope, a discharge gas fill inside the envelope, a phosphor coating adjacent to the inner surface of the envelope, and at least a barrier coating between the inner surface of the envelope and the phosphor coating. The barrier coating comprises a blend of alumina and at least one coloring pigment. | 06-18-2009 |
Gyorgy Wolfner, Budapest HU
Patent application number | Description | Published |
---|---|---|
20080279151 | METHOD AND DEVICE FOR PROCESSING DATA AND COMMUNICATION SYSTEM COMPRISING SUCH DEVICE - A method and a device for processing data are provided, the device includes a first network element sends a message to a second network element thereby informing the second network element about a change of attachment of a third network element. | 11-13-2008 |
20090303924 | PACKET DATA NETWORK SELECTION - According to an example embodiment, a method may include sending, by a mobile station in a wireless network, a dynamic service addition (DSA) message to a base station, the DSA message identifying a packet data network (PDN) by access point name (APN). The method may further include exchanging data with the indicated packet data network via the base station. | 12-10-2009 |
György Báthori, Budapest HU
Patent application number | Description | Published |
---|---|---|
20100021927 | CHOLESTEROL LOADED INSECT CELL MEMBRANES AS TEST SYSTEMS FOR ABC TRANSPORTER PROTEINS - The invention provides for a novel cholesterol loaded insect cell membrane preparation having an increased cholesterol level as compared to physiological cholesterol levels of insect cell membranes or to control insect cell membrane preparations without cholesterol loading, wherein said cholesterol loaded membrane preparation comprises an ABC transporter protein having an increased substrate transport activity due to increased cholesterol level of the membrane. The invention also relates to reagent kits comprising the preparations of the invention. The invention also relates to methods for manufacturing said preparations and methods for measuring any type of activity of the ABC transporters present in the cholesterol loaded membranes as well as studying or testing compounds and interaction of compounds and ABC transporters, in this assay systems. The invention also provides for a test system useful for testing whether ABC transporter proteins can be activated by cholesterol in an insect cell membrane. | 01-28-2010 |
György Báthori, Budapest HU
Patent application number | Description | Published |
---|---|---|
20100021927 | CHOLESTEROL LOADED INSECT CELL MEMBRANES AS TEST SYSTEMS FOR ABC TRANSPORTER PROTEINS - The invention provides for a novel cholesterol loaded insect cell membrane preparation having an increased cholesterol level as compared to physiological cholesterol levels of insect cell membranes or to control insect cell membrane preparations without cholesterol loading, wherein said cholesterol loaded membrane preparation comprises an ABC transporter protein having an increased substrate transport activity due to increased cholesterol level of the membrane. The invention also relates to reagent kits comprising the preparations of the invention. The invention also relates to methods for manufacturing said preparations and methods for measuring any type of activity of the ABC transporters present in the cholesterol loaded membranes as well as studying or testing compounds and interaction of compounds and ABC transporters, in this assay systems. The invention also provides for a test system useful for testing whether ABC transporter proteins can be activated by cholesterol in an insect cell membrane. | 01-28-2010 |
György Clememtis, Budapest HU
Patent application number | Description | Published |
---|---|---|
20090306117 | ROSUVASTATIN ZINC SALT - The present invention is related to rosuvastatin zinc salt of the Formula (I), process for preparation thereof and medicinal products containing said salt. Rosuvastatin zinc salt according to the present invention is prepared by reacting rosuvastatin with a zinc alcoholate, zinc enolate or an inorganic or organic zinc salt and isolating the thus obtained rosuvastatin zinc salt (2:1). | 12-10-2009 |
György Clememtis, Budapest HU
Patent application number | Description | Published |
---|---|---|
20090306117 | ROSUVASTATIN ZINC SALT - The present invention is related to rosuvastatin zinc salt of the Formula (I), process for preparation thereof and medicinal products containing said salt. Rosuvastatin zinc salt according to the present invention is prepared by reacting rosuvastatin with a zinc alcoholate, zinc enolate or an inorganic or organic zinc salt and isolating the thus obtained rosuvastatin zinc salt (2:1). | 12-10-2009 |
György Clementis, Siofok HU
Patent application number | Description | Published |
---|---|---|
20130225695 | METHOD FOR PREPARATION OF AN EXCIPIENT SUITABLE FOR PHARMACEUTICAL USE - The present invention is related to a method for purifying diatomaceous earth wherein the natural colloidal structure of the material is retained, which comprises preparing a suspension of diatomaceous earth in a liquid wherein diatomaceous earth is insoluble, separating diatomaceous earth from the suspension, treating diatomaceous earth with an inorganic or organic acid, heat-treating the thus obtained product at a temperature not higher than 300° C., subjecting the product obtained to oxidative treatment and drying the purified product. | 08-29-2013 |
György Clementis, Siofok HU
Patent application number | Description | Published |
---|---|---|
20130225695 | METHOD FOR PREPARATION OF AN EXCIPIENT SUITABLE FOR PHARMACEUTICAL USE - The present invention is related to a method for purifying diatomaceous earth wherein the natural colloidal structure of the material is retained, which comprises preparing a suspension of diatomaceous earth in a liquid wherein diatomaceous earth is insoluble, separating diatomaceous earth from the suspension, treating diatomaceous earth with an inorganic or organic acid, heat-treating the thus obtained product at a temperature not higher than 300° C., subjecting the product obtained to oxidative treatment and drying the purified product. | 08-29-2013 |
György Cselik, Budapest HU
Patent application number | Description | Published |
---|---|---|
20120157620 | AMINE-EPOXY ADDUCTS AND THEIR USE FOR PREPARING POLYUREA AND POLYUREA-POLYURETHANE COATINGS - The invention relates to amine-epoxy adducts with symmetrical and asymmetrical structures based on one hand on aliphatic, cycloaliphatic, araliphatic or aromatic mono-, di- and triamines, and on the other hand on aliphatic, cycloaliphatic and aromatic, mono-, di- or polyepoxy compounds, having an average molecular mass (M | 06-21-2012 |
György Domány, Budapest HU
Patent application number | Description | Published |
---|---|---|
20150284338 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF PYRIMIDINYL-PIPERAZINE DERIVATIVES - Our invention relates to trans-(4-{4-[2-(4-amino-cyclohexyl)-ethyl]-piperazin-1-yl}-5,6-dichloro-pyrimidin-2-yl)-methylamine dihydrochloride monohydrate, the process for the synthesis of this compound, the new (4,5-dichloro-6-piperazin-1-yl-pyirimidin-2-yl)-methylamine monohydrochlorid used as starting material in this synthesis, as well as the industrial process for the synthesis of trans-N-(4- {2-[4-(5,6-dichloro-2-methyl-amino-pyirimidin-4-yl-)piperazin-1-yl]-ethly}cyclohexyl-propionamide starting from trans-(4-{4-[2-(4-amino-cyclohexyl)-ethyl]-piperazin-1-yl}-5,6-dichloro-pyrimidin-2-yl)-methylamine dihydrochloride monohydrate. | 10-08-2015 |
György Dormán, Budapest HU
Patent application number | Description | Published |
---|---|---|
20100267711 | METHOD OF ENHANCING CELLULAR PRODUCTION OF MOLECULAR CHAPERONE, HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE CHAPERONE PRODUCTION AND THE PREPARATION THEREOF - A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). | 10-21-2010 |
20130303572 | NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES - Compounds of general formula (I), salts or solvates thereof and pharmaceutical compositions containing same: | 11-14-2013 |
György Dormán, Budapest HU
Patent application number | Description | Published |
---|---|---|
20100267711 | METHOD OF ENHANCING CELLULAR PRODUCTION OF MOLECULAR CHAPERONE, HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE CHAPERONE PRODUCTION AND THE PREPARATION THEREOF - A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). | 10-21-2010 |
20130303572 | NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES - Compounds of general formula (I), salts or solvates thereof and pharmaceutical compositions containing same: | 11-14-2013 |
György Egely, Budakeszi HU
Patent application number | Description | Published |
---|---|---|
20140098920 | METHOD FOR THE PRODUCTION OF RENEWABLE HEAT ENERGY - The subject of the invention is a process for heat production with nuclear interactions. During the process the gas is pumped through a stack of nanoparticles in a device featuring an internal and an external chamber via an inlet and an outlet opening, and the process is initiated by heating the device. Further, the subject of the invention is a device accomplishing said process. The device has an interconnected internal chamber, and surrounding said chamber there is an external chamber having at least one inlet and one exit opening. There are nanoparticles in the internal chamber. There is an impermeable wall between the two said chambers. The internal chamber is separated from the exit opening by a heat resistant, porous ceramic wall. There is a heating element on the internal side wall. | 04-10-2014 |
20140126679 | RENEWABLE ENERGY PRODUCTION PROCESS WITH A DEVICE FEATURING RESONANT NANO-DUST PLASMA, A CAVITY RESONATOR AND AN ACOUSTIC RESONATOR - The invention is a renewable energy production process with resonant nano-dust plasma, with the application of a cavity resonator and an acoustic resonator. During the process the acoustic resonator is placed inside the cavity resonator, and create a series of acoustic resonances with a complex plasma made of sub-micron sized carbon dust, hydrogen isotopes and other gases between 10 Pa and 500 kPa at about 2.000° C., thus creating oscillations and thus plasmon polaritons on the surface of carbon dust particles oscillating between 10 kHz-5 GHz and in the terahertz range, which in turn produces heat or electric energy, or creates a series of nuclear transmutations. The invention is an embodiment producing renewable heat, formed by a cavity resonator ( | 05-08-2014 |
György Falkay, Szeged HU
Patent application number | Description | Published |
---|---|---|
20150150842 | DESETHYLAMIODARONE COMPOSITIONS - The invention relates to a pharmaceutical composition comprising a compound selected from the group consisting of desethylamiodarone and pharmaceutically acceptable salts, hydrates and solvates thereof, together with pharmaceutically acceptable excipients, vehicle and/or carrier, as well as the pharmaceutical composition for use in the treatment and prevention of atrial fibrillation with fewer side effects than its parent compound. | 06-04-2015 |
György Haraszati, Budapest HU
Patent application number | Description | Published |
---|---|---|
20120261848 | METHOD TO CREATE REMOVABLE DENTAL PROSTHESIS, AND THE DENTAL PROSTHESIS MAKING THEREOF - The subject of the invention is a method to create removable dental prosthesis, and the dental prosthesis making thereof, which solution is suitable for quick and efficient production of removable dental prostheses. | 10-18-2012 |
György Juhász, Budapest HU
Patent application number | Description | Published |
---|---|---|
20100296096 | IMAGING OPTICAL INSPECTION DEVICE WITH A PINHOLE CAMERA - The invention relates to an imaging optical inspection setup for inspecting a sample ( | 11-25-2010 |
20120324368 | Object transfer method using gesture-based computing device - A file transfer method is operative in a mobile computing device having a display interface that supports gesture-based control operations. The mobile computing device includes a remote access client. One or more other computers associated with the user each maintain connections to a Web-based remote access service. The user desires to copy and/or move resources between first and second of his or her connected computers. According to the file transfer method, after receipt of data indicating a first gesture requesting a copy or move operation with respect to the resource in the file system, an overview of one or more target devices is displayed. The overview is a folder level view of all folders and files located on the target devices, which are the one or more other computers also having a connection (or capable of having a connection) to the Web-based remote access service. In addition to displaying the folder-level view, an additional display element is shown. This display element is a representation of the resource from which the copy or move operation has been requested. The display element is displayed as an overlay, and it is adapted to be selectively positioned (by the user) in the overview using a gesture. Thereafter, and upon receipt of data indicating a second gesture that has caused the representation to be positioned over an available transfer location within a computer connected to the Web-based remote access service, the copy or move operation is completed. | 12-20-2012 |
György Juhász, Budapest HU
Patent application number | Description | Published |
---|---|---|
20100296096 | IMAGING OPTICAL INSPECTION DEVICE WITH A PINHOLE CAMERA - The invention relates to an imaging optical inspection setup for inspecting a sample ( | 11-25-2010 |
20120324368 | Object transfer method using gesture-based computing device - A file transfer method is operative in a mobile computing device having a display interface that supports gesture-based control operations. The mobile computing device includes a remote access client. One or more other computers associated with the user each maintain connections to a Web-based remote access service. The user desires to copy and/or move resources between first and second of his or her connected computers. According to the file transfer method, after receipt of data indicating a first gesture requesting a copy or move operation with respect to the resource in the file system, an overview of one or more target devices is displayed. The overview is a folder level view of all folders and files located on the target devices, which are the one or more other computers also having a connection (or capable of having a connection) to the Web-based remote access service. In addition to displaying the folder-level view, an additional display element is shown. This display element is a representation of the resource from which the copy or move operation has been requested. The display element is displayed as an overlay, and it is adapted to be selectively positioned (by the user) in the overview using a gesture. Thereafter, and upon receipt of data indicating a second gesture that has caused the representation to be positioned over an available transfer location within a computer connected to the Web-based remote access service, the copy or move operation is completed. | 12-20-2012 |
György Kaptay, Miskolc HU
Patent application number | Description | Published |
---|---|---|
20160060743 | Method and apparatus for the production of carbon fibre reinforced aluminium matrix composite wires - The invention relates to a method for the production of carbon fibre reinforced aluminium matrix composite wires by drawing carbon fibres through molten salt and molten aluminium in such a way that the molten aluminium and the molten salt are spatially separated, and the carbon fibres are drawn through first the molten salt, then the molten aluminium separated from it. The invention further relates to an apparatus for the implementation of the method. | 03-03-2016 |
György Kaptay, Miskolc HU
Patent application number | Description | Published |
---|---|---|
20110185855 | METHOD TO PRODUCE MONOTECTIC DISPERSED METALLIC ALLOYS - The invention relates to a method for producing monotectic alloys with finely dispersed and homogeneously distributed second phase particles from two or more starting metals or alloys, in which the two or more metals or alloys are melted together or separately and the two or more, practically immiscible liquid metallic alloys are mixed to disperse the alloy of lower volume ratio with the other alloy of higher volume ratio, then the system is cooled below the eutectic temperature. The characteristic feature of the method is that at least one of the starting alloys contains stabilizing solid particles. | 08-04-2011 |
György Kaszás, Budapest HU
Patent application number | Description | Published |
---|---|---|
20100065202 | Procedure of Manufacturing a Neutron-Guiding Flat Surface - The subject of the invention is a procedure for manufacturing a neutron-guiding flat surface of low waviness in the course of which a thin plate coated by a material suitable for neutron reflection, advantageously of multilayered structure, is glued onto a significantly thicker carrier surface. The procedure is characterised by placing the thin neutron-reflecting plate onto a base surface of low flatness, typically of the order of magnitude of 10 | 03-18-2010 |
György Kaszás, Budapest HU
Patent application number | Description | Published |
---|---|---|
20100065202 | Procedure of Manufacturing a Neutron-Guiding Flat Surface - The subject of the invention is a procedure for manufacturing a neutron-guiding flat surface of low waviness in the course of which a thin plate coated by a material suitable for neutron reflection, advantageously of multilayered structure, is glued onto a significantly thicker carrier surface. The procedure is characterised by placing the thin neutron-reflecting plate onto a base surface of low flatness, typically of the order of magnitude of 10 | 03-18-2010 |
György Kéri, Budapest HU
Patent application number | Description | Published |
---|---|---|
20080207677 | Napthyridine Compounds As Rock Inhibitors - The present invention relates to compounds having a naphthyridine scaffold, and stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these naphthyridine derivatives together with pharmaceutically acceptable carrier, excipient and/or diluents. Said naphthyridine compounds have been identified as inhibitors of the protein kinase ROCK2, also known as Rho-kinase, and are useful for the treatment of cancers (tumor growth and metastases), erectile dysfunction, cardiovascular diseases, hypertension, angina pectoris, cerebral ischaemia, cerebral vasospasm, myocardial ischaemia, coronary vasospasm, heart failure, myocardial hypertrophy, atherosclerosis, restenosis, spinal cord injuries, neuronal degeneration, thrombotic disorders, asthma, glaucoma, inflammation, anti-viral diseases (e.g. HIV), and osteoporosis. | 08-28-2008 |
20080214583 | 7H-Pyrrolo[2,3-D]Pyrimidine Derivatives, As Well As Their Therapeutically Acceptable Salts, Pharmaceutical Preparations Containing Them And Process For Production The Active Agent - The invention relates to new 7H-pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for producing the active agent. The pharmaceutical preparation is adventageously antiphlogistic and analgetic one, a preparation reducing neuropathic hyperalgesia and rheumatic arthritis, a preparation for hindering destruction of bones chondrus, being applicable for treatment of other diseases, which may be connected with other inflammatory processes e.g. asthma, eczema or psoriasis. | 09-04-2008 |
20090018149 | 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections - Described are 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and pharmaceutically acceptable salts thereof, the use of these derivatives for the prophylaxis and/or treatment of mycobacteria-induced infections and opportunistic infections, as well as compositions containing at least one 4,5,6,7-tetrahydrobenzo[b]thiophene derivative and/or pharmaceutically acceptable salts thereof. Furthermore, the present application refers to the use of mycobacterial protein serine/threonine kinases for developing methods for detection and determination of these kinases for recognising and monitoring diseases and for controlling therapy of diseases. | 01-15-2009 |
20090298842 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor - Described herein is the discovery that certain mycobacterial serine/threonine protein kinases, particularly protein kinase G (PknG), are effective therapeutic targets for the treatment of mycobacterial infections. Furthermore, the present application refers to the use of mycobacterial serine/threonine protein kinases for developing methods for detection and determination of these kinases for recognizing and monitoring diseases and for controlling therapy of diseases. Additionally disclosed are novel 4,5,6,7-tetrahydrobenzo[b]thiophene compounds, benzo(g)quinoxaline compounds, and pharmaceutically acceptable salts thereof, and methods of using such compounds and salts thereof for the prophylaxis and/or treatment of virally and/or bacterially induced infections, particularly mycobacteria-induced infections, including opportunistic infections, as well as pharmaceutical compositions containing at least one 4,5,6,7-tetrahydrobenzo[b]thiophene compound and/or benzo(g)quinoxaline compound and/or pharmaceutically acceptable salts thereof in a pharmaceutically acceptable carrier. | 12-03-2009 |
20120164132 | Anticancer and immunomodulating molecules and fractions containing said molecules, and process for preparing said fractions and said molecules from fermented vegetal material, and their uses - Biologically active substances and fractions of wheat germ ferment/fermented wheat germ extract (FWGE), including formulation A250, the processes for their production, the pharmaceutical preparations containing them, and their uses. | 06-28-2012 |
20140057911 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVING BOTH AROMATIC AND HALOGENIC SUBSTITUENTS - Certain 4,6-disubstituted aminopyrimidine derivatives having both aromatic and halogenic substituents. | 02-27-2014 |
20140336191 | QUINOLINYLOXYPHENYLSULFONAMIDES - The present invention relates to quinolinyloxyphenylsulfonamides and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these quinolinyloxyphenylsulfonamide compounds as well as pharmaceutical compositions containing at least one of these compounds together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said quinolinyloxyphenylsulfonamides are useful for prophylaxsis, treatment and/or after-treatment of hyperproliferative disorders, such as cancer, tumors and particularly cancer metastases. | 11-13-2014 |
20150368209 | 4-Pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (PLK1) for the treatment of cancer and their use for the treatment of bacterial infections - The present invention relates to 4-pyrimidinylamino-benzenesulfonamide derivatives of general formula (I) and pharmaceutically acceptable salts, solvates, hydrates, regioisomeric and polymorphic forms thereof, processes for manufacturing of them, the use of them, as well as pharmaceutical compositions containing at least one of them as pharmaceutically active agent(s) together with pharmaceutically acceptable carrier, excipient and/or diluents, especially for the inhibition of polo-like kinases (PLKs) and the treatment of cancer. Said 4-pyrimidinylamino-benzenesulfonamide compounds have been also identified as new drug candidates for the prevention and/or treatment of infectious diseases like bacterial diseases e.g. tuberculosis, including the currently multidrug-resistant tuberculosis (MDR-TB), extensively drug-resistant tuberculosis (XDR-TB) as well as for preventing tuberculosis. | 12-24-2015 |
György Kéri, Budapest HU
Patent application number | Description | Published |
---|---|---|
20090298842 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor - Described herein is the discovery that certain mycobacterial serine/threonine protein kinases, particularly protein kinase G (PknG), are effective therapeutic targets for the treatment of mycobacterial infections. Furthermore, the present application refers to the use of mycobacterial serine/threonine protein kinases for developing methods for detection and determination of these kinases for recognizing and monitoring diseases and for controlling therapy of diseases. Additionally disclosed are novel 4,5,6,7-tetrahydrobenzo[b]thiophene compounds, benzo(g)quinoxaline compounds, and pharmaceutically acceptable salts thereof, and methods of using such compounds and salts thereof for the prophylaxis and/or treatment of virally and/or bacterially induced infections, particularly mycobacteria-induced infections, including opportunistic infections, as well as pharmaceutical compositions containing at least one 4,5,6,7-tetrahydrobenzo[b]thiophene compound and/or benzo(g)quinoxaline compound and/or pharmaceutically acceptable salts thereof in a pharmaceutically acceptable carrier. | 12-03-2009 |
20110318409 | FRACTIONS OF WHEAT GERM FERMENT - The invention concerns wheat germ ferment, its biologically active fractions, the process for their production, the pharmaceutical preparations containing them and their uses. | 12-29-2011 |
20120258968 | 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY - The invention relates compounds of general formula (I) and pharmaceutically acceptable salts and solvates thereof wherein | 10-11-2012 |
20120277231 | QUINOLINYLOXYPHENYLSULFONAMIDES - The present invention relates to quinolinyloxyphenylsulfonamides and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these quinolinyloxyphenylsulfonamide compounds as well as pharmaceutical compositions containing at least one of these compounds together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said quinolinyloxyphenylsulfonamides are useful for prophylaxsis, treatment and/or after-treatment of hyperproliferative disorders, such as cancer, tumors and particularly cancer metastases. | 11-01-2012 |
György KeserÜ, Budapest HU
Patent application number | Description | Published |
---|---|---|
20090312299 | Isolated Isomers of Norelgestromin and Methods of Making and Using the Same - The invention is directed to a process of preparing substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3E- and -3Z-oxime isomers, as well as a process for the synthesis of the mixture of isomers and the pure isomers. The invention also relates to substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene20-yn-3-one-3E-oxime and substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3Z-oxime isomer. Further aspects of the invention include a composition comprising substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene20-yn-3-one-3E-oxime or substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3Z-oxime isomer, and methods of treatment using said compositions. | 12-17-2009 |
György KeserÜ, Budapest HU
Patent application number | Description | Published |
---|---|---|
20090312299 | Isolated Isomers of Norelgestromin and Methods of Making and Using the Same - The invention is directed to a process of preparing substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3E- and -3Z-oxime isomers, as well as a process for the synthesis of the mixture of isomers and the pure isomers. The invention also relates to substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene20-yn-3-one-3E-oxime and substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3Z-oxime isomer. Further aspects of the invention include a composition comprising substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene20-yn-3-one-3E-oxime or substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3Z-oxime isomer, and methods of treatment using said compositions. | 12-17-2009 |
György Kõvári, Budapest HU
Patent application number | Description | Published |
---|---|---|
20150276164 | LIGHT COVER - According to some embodiments, a light cover has an axis extending vertically from a threaded base portion to an end portion opposite the threaded base portion. The light cover may include a vertically open, pear-shaped first half portion (e.g., formed of plastic). The light cover may further include a vertically open, pear-shaped second half portion coupled to the first half portion to form a cavity to hold an illuminating bulb portion of a compact fluorescent lamp. The first and second half portions together may form an outer surface contoured substantially in the shape of an incandescent light bulb. | 10-01-2015 |
20160099140 | ADHESIVE-LESS ASSEMBLY FOR ELECTRONIC COMPACT FLUORESCENT LAMPS - A collar includes two sections that join together in an adhesive-less manner to form an aperture, an arm with a distally-located pawl extending from a base of each section, a frame on the other section at a position corresponding to the arm, a lower clamp located on the sections, an upper clamp including a distally-located projection extending from the base surface, first and second flexible clamps located at opposing ends of the aperture. A gas discharge tube lighting assembly includes a discharge tube collar, a discharge tube having a stem assembly with a first portion fitting within the discharge tube and a second portion having a seal ring with a diameter greater than the discharge tube outer diameter, the collar and tube connected by adhesive-less mechanical forces exerted on the upper, lower, and first and second flexible clamps with the discharge tube located partially in the aperture. | 04-07-2016 |
György Krasznai, Budapest HU
Patent application number | Description | Published |
---|---|---|
20090215757 | Process for Preparation of High-Purity Meloxicam and Meloxicam Potassium Salt - The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium salt monohydrate is produced. Said salt is subsequently treated with mineral or organic acid to yield high-purity meloxicam. | 08-27-2009 |
20130281694 | METHOD FOR PREPARING ROSUVASTATIN SALTS - The present invention is related to methods for the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S,6E)-dihydroxy-hept-6-enoic acid, intermediates thereof and methods for producing said intermediates. | 10-24-2013 |
20130338360 | METHOD FOR THE PREPARATION OF HIGH-PURITY PHARMACEUTICAL INTERMEDIATES - The present invention is related to intermediates useful in the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid and polymorphs of said intermediates, methods for preparation thereof and use thereof. | 12-19-2013 |
20140142303 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS - The invention relates to a process for the preparation of 5-chloro-N-({(5-S)-2-oxo3-[4-(3-oxo-morj)holine-4-yl)-phenyl]-1,3-oxazolidine-5-yl}-methyl) thiophen-2-carboxamide having the INN rivaroxaban. The process is characterized by the reactions according to claim | 05-22-2014 |
György Krasznai, Budapest HU
Patent application number | Description | Published |
---|---|---|
20090215757 | Process for Preparation of High-Purity Meloxicam and Meloxicam Potassium Salt - The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium salt monohydrate is produced. Said salt is subsequently treated with mineral or organic acid to yield high-purity meloxicam. | 08-27-2009 |
20120035162 | PROCESS FOR PREPARATION OF HIGH-PURITY MELOXICAM AND MELOXICAM POTASSIUM SALT - The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium salt monohydrate is produced. Said salt is subsequently treated with mineral or organic acid to yield high-purity meloxicam. | 02-09-2012 |
György Levay, Budapest HU
Patent application number | Description | Published |
---|---|---|
20100075975 | MEDICAMENT FOR THE ENHANCEMENT OF COGNITIVE FUNCTION AND NEUROPROTECTION - The invention relates the use of 4-chloro-5-{2-[4-(6-fluoro-1,2-benz[d]isoxazole-3-yl)piperidin-1-yl]ethyl-amino}-2-methyl-3-(2H) pyridazinone of the Formula (I) | 03-25-2010 |
György Lévay, Budapest HU
Patent application number | Description | Published |
---|---|---|
20090306144 | PYRIDINE DERIVATIVES OF ALKYL OXINDOLES AS 5-HT7 RECEPTOR ACTIVE AGENTS - New 3,3-disubstituted indol-2-one derivatives of the general formula (I) | 12-10-2009 |
György Panyi, Debrecen HU
Patent application number | Description | Published |
---|---|---|
20110059064 | Vm23 and Vm24, two scorpion peptides that block human T-lymphocyte potassium channels (sub-type Kv1.3) w/High Selectivity and Decrease the in vivo DTH-responses in Rats - Potassium channels Kv1.3 are known to be implicated in immunological diseases and graft rejections. Disclosed are peptides capable of blocking with high affinity and specificity potassium channels Kv1.3, their pharmaceutical compositions, and methods for their use to block Kv1.3 potassium channels, to treat various immunological conditions and to diagnostic applications. Methods for their chemical synthesis and correct folding are also disclosed. Exemplary peptides correspond to protein components (Vm23 and Vm24) isolated from the venom of the Mexican scorpion | 03-10-2011 |
György Panyi, Debrecen HU
Patent application number | Description | Published |
---|---|---|
20110059064 | Vm23 and Vm24, two scorpion peptides that block human T-lymphocyte potassium channels (sub-type Kv1.3) w/High Selectivity and Decrease the in vivo DTH-responses in Rats - Potassium channels Kv1.3 are known to be implicated in immunological diseases and graft rejections. Disclosed are peptides capable of blocking with high affinity and specificity potassium channels Kv1.3, their pharmaceutical compositions, and methods for their use to block Kv1.3 potassium channels, to treat various immunological conditions and to diagnostic applications. Methods for their chemical synthesis and correct folding are also disclosed. Exemplary peptides correspond to protein components (Vm23 and Vm24) isolated from the venom of the Mexican scorpion | 03-10-2011 |
20150087603 | MODIFIED PEPTIDE TOXINS - The invention relates to toxin peptides capable of selectively inhibiting a Kv1.3 potassium channel protein. The toxin peptides of the invention are modified anuroctonus scorpion toxin peptides. | 03-26-2015 |
György Rabloczky, Budapest HU
Patent application number | Description | Published |
---|---|---|
20100048627 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE PREVENTION OR TREATMENT OF DIABETES - The invention refers to a synergistic pharmaceutical combination which comprises (a) a first pharmaceutical composition containing an antidiabetic or anti-hyperlipidemic active agent and one or more conventional carrier(s), and (b) a second pharmaceutical composition containing a hydroximic acid derivative of the formula I and one or more conventional carrier(s). The pharmaceutical combination is suitable for the prevention or treatment of, among others, diabetes mellitus. | 02-25-2010 |
György Rabloczky, Budapest HU
Patent application number | Description | Published |
---|---|---|
20100048627 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE PREVENTION OR TREATMENT OF DIABETES - The invention refers to a synergistic pharmaceutical combination which comprises (a) a first pharmaceutical composition containing an antidiabetic or anti-hyperlipidemic active agent and one or more conventional carrier(s), and (b) a second pharmaceutical composition containing a hydroximic acid derivative of the formula I and one or more conventional carrier(s). The pharmaceutical combination is suitable for the prevention or treatment of, among others, diabetes mellitus. | 02-25-2010 |
György Ruzsics, Budapest HU
Patent application number | Description | Published |
---|---|---|
20120330018 | PROCESS FOR PREPARING PHARMACEUTICAL COMPOUNDS AND INTERMEDIATE COMPOUNDS - The object of the present invention is a process for preparing the 2-acetoxy-5-(2-fluor-α-cyclopropyl-carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-tieno[3,2-c]pyridine (prasugrel) of the formula (I). The process starts form crystalline 5-trityl-4,5,6,7-tetrahydro-tieno[3,2-c]pyridine of the formula (VI). Further objects of the present invention are two novel crystalline forms of 5-trityl-4,5,6,7-tetrahydro-tieno[3,2-c]pyridine of the formula (VI) and the use thereof for preparing the compound of the formula (V) and process preparing thereof. | 12-27-2012 |
20130030183 | PROCESS FOR PREPARING A PHARMACEUTICAL COMPOUND - The object of the present invention is a one-pot process for preparing the 2-acetoxy-5-(2-fluoro-α-cyclopropyl-carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-tieno[3,2-c]-pyridine (prasugrel) of the formula (I) by reacting the 5,6,7,7a-tetrahydro-4H-tieno[3,2-c]-pyridine-2-on of the formula (II) with 2-bromo-1-cyclopropyl-2-(2-fluorophenyl)-etanone of the formula (III) or with 2-chloro-1-cyclopropyl-2-(2-fluorphenyl)-etanone of the formula (IIIa) and acetylating of the formed compound of the formula (IV), wherein the reaction is carried out in the presence of an organic base with an acetylation agent without isolating the compound of the formula (IV). The coupling and acetylation are carried out in the presence of the same organic base such as triethylamine, N,N-diisopropyl-ethylamine or pyridine. At the end of the process the prasugrel of the formula (I) is purified by recrystallization from an organic solvent or a mixture of solvents. | 01-31-2013 |
György Turóczi, Godollo HU
Patent application number | Description | Published |
---|---|---|
20140377239 | ACTIVE AGENTS AGAINST PSEUDOMONAS SPECIES CAUSING ROTTING DISEASES IN MUSHROOM PRODUCTION, THEIR USE AND COMPOSITIONS CONTAINING THEM - A biological material is disclosed for exerting antagonism against the mushroom pathogen | 12-25-2014 |
20150147296 | COPPER RESISTANT, FENGYCIN-PRODUCING BACILLUS MOJAVENSIS STRAIN FOR CONTROLLING VEGETABLE PATHOGENS, ITS USE AND COMPOSITIONS CONTAINING IT - A biological material is disclosed for exerting antagonism against vegetable pathogens, which contains | 05-28-2015 |
György Újfalussy, Budapest HU
Patent application number | Description | Published |
---|---|---|
20150094345 | PHARMACEUTICAL FORMULATION HAVING IMPROVED STABILITY - The present invention is related to a pharmaceutical formulation containing ramipril with improved stability, which comprises ramipril and a desintegrant directly granulated with a binder. | 04-02-2015 |
György Várady, Budapest HU
Patent application number | Description | Published |
---|---|---|
20150111770 | QUANTITATIVE DETERMINATION OF BIOMARKERS IN THE ERYTHROCYTE MEMBRANE - This invention relates to determination of quantitative expression of plasma membrane proteins as biomarkers in the erythrocytes. The invention includes simple, quantitative assay platforms which can be made available in most diagnostic laboratories. The platform allows performing personalized, quantitative tests for the direct expression level of a wide range of membrane proteins from small volume blood samples and connecting them to individual genetic variability, disease conditions, disease stages and complications, treatment protocols, pharmacological responses, or toxic side effects. | 04-23-2015 |
György Visky, Budapest HU
Patent application number | Description | Published |
---|---|---|
20090187032 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF 17alpha-ACETOXY-11beta-[4-(N,N-DIMETHYL-AMINO)-PHENYL]-19-NORPREGNA-4,9-D- IENE-3,20-DIONE AND NEW INTERMEDIATES OF THE PROCESS - The present invention relates to a new industrial process for the synthesis of solvate-free 17α-acetoxy-11β-[4-(N,N-dimethyl-amino)-phenyl]-19-norpregna-4,9-diene-3,20-dione [CDB-2914] of formula (I) which is a strong antiprogestogene and antiglucocorticoid agent. The invention also relates to compounds of formula (VII) and (VIII) used as intermediates in the process. | 07-23-2009 |
20100137622 | INDUSTRIAL METHOD FOR THE SYNTHESIS OF 17-ACETOXY-11beta-[4-(DIMETHYLAMINO)-PHENYL]-21-METHOXY-19-NORPREGNA-4,9-- DIEN-3,20-DIONE AND THE KEY INTERMEDIATES OF THE PROCESS - The present invention relates to a process for the synthesis of the known 17-acetoxy-11-β-[4-(dimethyl amino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione (further on CDB-4124) of formula (I) from 3,3-[1,2-ethandiyl-bis(oxy)]-oestr-5(10),9(11)-dien-17-one of formula (II). Compound CDB-4124 belongs to the group of anti-hormones. The process has the following steps: i) formation of an epoxide; ii) addition of hydrogen cyanide; iii) silylation of a hydroxyl group; iv) reaction with 4-(dimethylamino)-phenyl magnesium bromide Grignard reagent in the presence of CuCl (Teutsch reaction); v) silylation of a hydroxyl group with trimethyl chlorosilane; vi) reaction with diisobutyl aluminum hydride and after addition of acid to the reaction mixture; vii) methoxy-methylation with methoxy-methyl Grignard reagent formed in situ, while hydrolyzing the trimethylsilyl protective groups; viii) oxidation of a hydroxyl group with dicyclohexyl carbodiimide in the presence of dimethyl sulfoxide and a strong organic acid (Swern oxidation), and in given case after purification by chromatography; ix) acetylation of a hydroxyl group with acetic anhydride in the presence of perchloric acid, and in given case, purification by chromatography. The invention also relates to new intermediates of the process. | 06-03-2010 |
György Visky, Budapest HU
Patent application number | Description | Published |
---|---|---|
20100137622 | INDUSTRIAL METHOD FOR THE SYNTHESIS OF 17-ACETOXY-11beta-[4-(DIMETHYLAMINO)-PHENYL]-21-METHOXY-19-NORPREGNA-4,9-- DIEN-3,20-DIONE AND THE KEY INTERMEDIATES OF THE PROCESS - The present invention relates to a process for the synthesis of the known 17-acetoxy-11-β-[4-(dimethyl amino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione (further on CDB-4124) of formula (I) from 3,3-[1,2-ethandiyl-bis(oxy)]-oestr-5(10),9(11)-dien-17-one of formula (II). Compound CDB-4124 belongs to the group of anti-hormones. The process has the following steps: i) formation of an epoxide; ii) addition of hydrogen cyanide; iii) silylation of a hydroxyl group; iv) reaction with 4-(dimethylamino)-phenyl magnesium bromide Grignard reagent in the presence of CuCl (Teutsch reaction); v) silylation of a hydroxyl group with trimethyl chlorosilane; vi) reaction with diisobutyl aluminum hydride and after addition of acid to the reaction mixture; vii) methoxy-methylation with methoxy-methyl Grignard reagent formed in situ, while hydrolyzing the trimethylsilyl protective groups; viii) oxidation of a hydroxyl group with dicyclohexyl carbodiimide in the presence of dimethyl sulfoxide and a strong organic acid (Swern oxidation), and in given case after purification by chromatography; ix) acetylation of a hydroxyl group with acetic anhydride in the presence of perchloric acid, and in given case, purification by chromatography. The invention also relates to new intermediates of the process. | 06-03-2010 |